APA (7th ed.) Citation

S, N., H, M., KI, Y., N, S., H, I., S, M., . . . N, A. (2026). HLA-DRB3/4/5-based susceptibility profiles in nivolumab-induced type 1 diabetes and interstitial lung disease. Frontiers in immunology, 17, 1840622. https://doi.org/10.3389/fimmu.2026.1840622

Chicago Style (17th ed.) Citation

S, Nishikido, et al. "HLA-DRB3/4/5-based Susceptibility Profiles in Nivolumab-induced Type 1 Diabetes and Interstitial Lung Disease." Frontiers in Immunology 17 (2026): 1840622. https://doi.org/10.3389/fimmu.2026.1840622.

MLA (9th ed.) Citation

S, Nishikido, et al. "HLA-DRB3/4/5-based Susceptibility Profiles in Nivolumab-induced Type 1 Diabetes and Interstitial Lung Disease." Frontiers in Immunology, vol. 17, 2026, p. 1840622, https://doi.org/10.3389/fimmu.2026.1840622.